Abstract 141P
Background
In antibody-mediated oncotherapy, IgG monoclonal antibodies have been the class of choice for the treatment of different cancers. However, tumour-antigen specific IgE antibodies are emerging as a new avenue for cancer therapy. This class of antibody have a high affinity for cognate Fcε receptors expressed on tumour-resident immune cells, such as macrophages and mast cells, and a lack of inhibitory Fc receptors, offering the chance to activate anti-tumour responses in tissues. Recently, a tolerable safety profile and anti-tumour efficacy of an IgE antibody recognizing the tumour-associated antigen, folate receptor α (FRα), has been shown in the first-in-class clinical trial of this agent.
Methods
We engineered a monoclonal IgE antibody, with human constant domains, recognising CSPG4 to target human melanoma. In vitro Fab-mediated antitumour effects, and mediated antibody-dependent cellular cytotoxicity (ADCC) against melanoma cells by immune effector cells were evaluated. CSPG4 antigen may be cleaved and released from the surface of tumour cells, and may bind to anti-CSPG4 antibodies, preventing them from engaging tumour cells and impairing their anti-tumour efficacy; or complexes of shed CSPG4 may cross-link anti-CSPG4 IgE engaged with basophils, which could potentiate degranulation and type I hypersensitivity. CSPG4 antigen shedding was measured in melanoma cell supernatant and in human sera. As an early evaluation of safety, we tested the propensity for CSPG4 IgE to induce RBL-SX38 degranulation in the presence of melanoma patient sera, and in unfractionated patient blood in basophil activation tests (BAT).
Results
CSPG4 IgE bound to melanoma tumours, induced Fab-mediated antitumour effects, and mediated ADCC against melanoma cells. We measured minimal shedding of the CSPG4 antigen in melanoma cell supernatants. Low levels of CSPG4 were detected in the circulation of melanoma patients and healthy subjects, with no significant difference in levels between the groups. CSPG4 IgE did not trigger RBL-SX38 degranulation and did not activate basophils in the BAT assay, suggesting lack of propensity to trigger anaphylaxis.
Conclusions
Our findings suggest that CSPG4 IgE may be an efficacious and safe immunotherapy for melanoma.
Legal entity responsible for the study
The authors.
Funding
Epsilogen Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - Peripheral immunotype classification for monitoring Soft Tissue Sarcoma patients
Presenter: Jani Sofia Almeida
Session: Poster Display
36P - Expression of germinal center B cell- and Th17 cell-related transcripts are prognostic of soft-tissue sarcoma patient outcomes
Presenter: Giulia Petroni
Session: Poster Display
38P - Machine learning-based pathomics model to predict the infiltration of Treg and prognosis in IDH-wt GBM
Presenter: Shaoli Peng
Session: Poster Display
40P - The role of low avidity tumour-specific CD8+ T cells in immunotherapeutic response to anti-PD-1
Presenter: Doreen Lau
Session: Poster Display
41P - Contrasting drivers of response to immunotherapy across solid tumour types: results from analysis of >2500 cases
Presenter: Danwen Qian
Session: Poster Display
42P - TCCIA: A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy
Presenter: Jian-Guo Zhou
Session: Poster Display
43P - Immune and tumor cells expression of VISTA in a panel of cancer indications: A strategy to inform selection of patients treated with anti-VISTA
Presenter: Pierre Launay
Session: Poster Display
44P - Exploratory Analysis of Peripheral Pharmacodynamic (PD) Biomarkers After Sitravatinib (Sitra) and Tislelizumab (TIS) in Advanced Solid Tumors: SAFFRON-103
Presenter: Yi-Long Wu
Session: Poster Display
45P - Protein biomarkers associated with organ-specific immune-related toxicity and response to management identified by proteome analysis of extracellular vesicles from plasma
Presenter: Anders Kverneland
Session: Poster Display